MODL-05 Metronomic Intrathecal Delivery of CDK4/6 Inhibitors in Preclinical Models of Pediatric Brain Tumors

INTRODUCTION: CDK4/6 inhibitors have shown promise against central nervous system (CNS) tumors in vitro. This class of drugs relies on long-term exposure. Their use in early phase clinical studies in children with CNS tumors has defined dose limitations due to systemic toxicity. We have sought to ci...

Descripción completa

Detalles Bibliográficos
Autores principales: Guadix, Sergio, Martin, Brice, Laramee, Madeline, Dahmane, Nadia, Thomas, Craig, Souweidane, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Preclinical Models/Experimental Therapy/Drug Discovery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164952/
http://dx.doi.org/10.1093/neuonc/noac079.628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164952/
http://dx.doi.org/10.1093/neuonc/noac079.628

Ejemplares similares